Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
44.68%
↑ 27% above average
Average (30q)
35.31%
Historical baseline
Range
High:971.57%
Low:-69.53%
Volatility
2948.7%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 44.68% |
| Q2 2025 | -49.87% |
| Q1 2025 | 46.29% |
| Q4 2024 | 71.53% |
| Q3 2024 | 36.22% |
| Q2 2024 | 11.80% |
| Q1 2024 | -8.38% |
| Q4 2023 | -6.90% |
| Q3 2023 | -28.89% |
| Q2 2023 | 58.92% |
| Q1 2023 | -6.55% |
| Q4 2022 | 2.43% |
| Q3 2022 | -0.02% |
| Q2 2022 | -1.15% |
| Q1 2022 | -11.01% |
| Q4 2021 | 7.47% |
| Q3 2021 | 32.41% |
| Q2 2021 | -2.03% |
| Q1 2021 | 971.57% |
| Q4 2020 | 88.23% |
| Q3 2020 | -54.19% |
| Q2 2020 | -7.04% |
| Q1 2020 | 5.67% |
| Q4 2019 | 5.08% |
| Q3 2019 | -46.21% |
| Q2 2019 | -69.53% |
| Q1 2019 | 6.48% |
| Q4 2018 | 0.00% |
| Q1 2018 | -2.47% |
| Q4 2017 | 0.00% |
| Q1 2017 | 0.00% |